Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on June 22, 2026. The filing discloses a strategic co-marketing collaboration under Item 7.01 (Regulation FD Disclosure) regarding a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on the announcement of a new commercial partnership and does not contain audited or unaudited financial statements.
Material Changes and Strategic Developments
- New Partnership: LifeMD entered into a Master Services Agreement and Statement of Work with Antares Pharma, Inc. (a subsidiary of Halozyme, Inc.).
- Role Definition: LifeMD serves as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program.
- Operational Scope: The program launches in July 2026, initially available in 37 states. LifeMD's affiliated medical group will evaluate patients, and LifeMD's pharmacy will serve as the preferred dispensing pharmacy.
- Investment Structure: Both parties will jointly invest in consumer education and promotional initiatives. A joint steering committee will oversee quarterly budget approvals.
- Term and Termination: The agreement has an initial three-year term with automatic one-year renewals. Either party may terminate the Statement of Work if budgeted marketing investments are not met for two consecutive quarters.
Guidance, Outlook, and Risks
Outlook: Management anticipates the program will expand awareness of testosterone deficiency and improve patient access. The launch is scheduled for July 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Commercial launch and adoption uncertainties.
- Changes in federal or state laws governing telehealth prescribing of controlled substances.
- Regulatory and compliance requirements applicable to telehealth, pharmacy, and pharmaceutical promotion.
- Failure to meet joint marketing investment budgets, which could trigger termination of the Statement of Work.
Investor Verification Checklist
- Verify the specific financial terms and revenue-sharing models within the Master Services Agreement (not detailed in this 8-K).
- Confirm the list of 37 states where the program will initially launch and any regulatory hurdles in those jurisdictions.
- Monitor the July 2026 launch date for any delays or scope changes.
- Review the quarterly marketing investment budgets to assess the risk of early termination due to unmet spending targets.
- Check for updates on regulatory changes regarding telehealth prescribing of controlled substances that could impact the business model.